Prevalence of Metabolic Syndrome in Patients with Poly Cystic Ovarian Syndrome in Ahvaz

Document Type : Original Article


1 Department of Endocrinology, Diabetes Research Center , Ahvaz Jundishapur University of Medical Science.

2 Department of Obstetric & Gynecology. Ahvaz Jundishapur University of Medical Science.

3 Intern of Ahvaz Jundishapur University of Medical Science .

4 Intern of Ahvaz Jundishapur University of Medical Science


Background and Objective: In different studies, the prevalence of metabolic syndrome outbreak has been reported as high as 7-43% among the women with polycystic ovary syndrome (PCOS). This study was performed to determine the prevalence and predictors of the metabolic syndrome in PCOS women in Ahvaz.
Subjects and Methods: In an epidemiologic descriptive study, a total number of 53 women who attended the endocrinology clinic in Ahvaz from 2007 through 2008, and were diagnosed as PCOS, according to the Rotterdam criteria, were enrolled in the study. The prevalence of metabolic syndrome was studied on the basis of the  criteria explained by American National Cholesterol Panel (ATP-III criteria)
Result: Fifty three women with the mean age of 24 ± 6.8 years were studied in this research. Prevalence of metabolic syndrome in  women of Ahvaz was estimated to be as 13.5%, and the prevalence for individual components comprising the metabolic syndrome were: fasting glucose blood concentrations greater than or equals to 110 mg/dl in 4 patient (7.7%), hypertension in 4 patients (7.7%), waist circumference greater than or equals to 88 cm in 14 patients (34.1%), HDL less than 40 mg/dl in 12 patients (24%), triglyceride greater than or equals to 150 mg/dl in 5 patients (9.4%), IFG in 17 patients (32.7%), diabetes in 3 patients (5.8%) and dislipidemia in 31 patients (60%).
Conclusions: The Metabolic Syndrome and its elements occur frequently in women with PCOS that places them at risk for cardiovascular diseases, therefore screening for these disturbances is recommended.
Sci Med J 2012; 10(6):595-604


1-Speroff L. Anuvulation the Polycyctic Ovary. In: Speroff L, Fritz MA, editors. Clinical Gynecology Endocrinology and Infertility. 7th ed. Philadelphia: Lippincott Williams & Wilkins; 2005. p. 470-71.
2-Rinehart RD. Endocrine disorders. In: Berek JS, editor. Berek & Novak’s Gynecology. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 1076- 9.
3-Cunningham FG. Polycyctic Ovarian syndrome and hyperandrogenism. In: Schorge JO, Schaffer JI, Halvorson LM, Hoffman BL, Bradshaw KD, Cunningham FG, editors. Williams gynecology. 5th ed. New York: McGraw-Hill; 2008. p. 379-86.
4-Bulun SE, Adashi EY. The physiology and pathology of the female reproductive axis. In: Kronenberg HM, Melmed S, Polonsky KS, Larsen PR, editors. Williams textbook of endocrinology. 11th ed. Philadelphia: Saunders; 2008. p. 579-85.
5-Ruderman N, Schulman G. The metabolic syndrome. In: Jameson D, editor. Endocrinology. 5th ed. London: Churchil and Livingstone; 2006. p. 1158.
6-Apridonidze T, Essah PA, Iuorno MJ, Nestler JE. Prevalence and characteristics of the metabolic syndrome in women with polycystic Ovary syndrome. J Clin Endocrinol Metabol. 2005; 90(4): 1929–35. PMID: 15623819.
7-Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA. Metabolic syndrome in polycystic ovary syndrome (PCOS): Lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J of Endocrinol. 2006; 154(1): 141-5. PMID: 16382003.
8-Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN. PCOS/Troglitazone study group prevalence and predictors of the metabolic syndrome in women with polycystic Ovary syndrome. J Cli Endocrinol Metabol. 2006; 91(1): 48-53. PMID: 16249284.
9-Soares EM, Azevedo GD, Gadelha RG, Lemos TM, Maranhão TM. Prevalence of the metabolic syndrome and its components in brazilian women with polycystic Ovary syndrome. Fertil Steril. 2008; 89(3): 649-55. PMID: 17543961.
10-Weerakiet S, Bunnag P, Phakdeekitcharoen B, Wansumrith S, Chanprasertyothin S, Jultanmas R, et al. Prevalence of the metabolic syndrome in asian women with polycystic Ovary syndrome: Using the international diabetes federation criteria. Gynecol Endocrinol. 2007; 23(3): 153-60. PMID: 17454169.
11-Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril. 2007; 88(5): 1389-95. PMID: 17462641.
12-Barber TM, Wass JAH, McCarthy MI, Franks S. Metabolic characteristics of women with polycystic Ovaries and Oligo-amenorrhoea but normal androgen levels: Implications for the management of polycystic Ovary syndrome. Clin Endocrinol. 2006; 66(4): 513-7. PMID: 17371468.
13-Pekhlivanov B, Kaleva-Khodzheva N, Orbetsova M, Mitkov M. Metabolic syndrome in women with polycystic Ovary syndrome. Akush Ginekol (Sofiia). 2007; 46(9): 37-40. PMID: 18646307.
14-Goverde AJ, Van Koert AJ, Eijkemans MJ, Knauff EA, Westerveld HE, Fauser BC, et al. Indicators for metabolic disturbances in anovulatory women with polycystic Ovary syndrome diagnosed according to the Rotterdam consensus criteria. Hum Reprod. 2009; 24(3): 710-7. PMID: 19095675.
15-Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY, et al. Cardiovascular risks and metabolic syndrome in Hong Kong chinese women with polycystic Ovary syndrome. Hum Reprod. 2008; 23(6): 1431-8. PMID: 18359783.
16-Lankarani M, Vali-Zadeh N, Heshmat R, Shafaei AR, Amini MR, Noori M, et al. Evaluation of dyslipidemia in polycystic Ovary syndrome. Iranian Journal of Diabetes and Lipid Disorders. 2005; 4(2): 79-88. [Persian].
17-Holte J, Bergh C, Little H. Serum lipoprotein lipid profile in women with the poly cystic Ovary syndrome: Relation to antropometric, endocrine and metabolic variables. Clinical Endocrinology (Oxford). 1994; 41: 463-71.